1.82 (-%)
As of Oct 30, 2024
Source:
We are a clinical stage biotechnological company, employing our core proprietary technologies to develop best-in-class products in the field of immuno-oncology. Our product candidates, based on gene-edited T-cells that express chimeric antigen receptors, or CARs, seek to harness the power of the immune system to target and eradicate cancer cells. We believe that CAR-based immunotherapy is one of the most promising areas of cancer research, representing a new paradigm for cancer treatment.
Country | France |
Headquarters | paris, lle-de-france |
Phone Number | 33181691600 |
Industry | manufacturing |
CEO | Andr Choulika |
Website | cellectis.com |